VIMTALABS

Vimta Labs share price & financials

India's #1 CRO in pharma analytical & food testing, plus preclinical, environment & electronics testing labs.

Price: ₹571.4
Market cap: ₹2.5k Cr
Sector: Healthcare
Calls analysed: 6

Latest concall · Q1 FY27 · call held 20 Jul 2026

Vimta Labs Q1 FY27

EBITDA ₹41.1 cr +16%EBITDA Margin 36.4% PAT ₹21 cr +11%PAT Margin 18.6%

What went well

Total income of INR112.9 crores, up 13.7% YoY, demonstrating resilient performance despite mixed demand.
EBITDA of INR41.1 crores, up 16% YoY, with strong EBITDA margins of 36.4%, significantly above industry benchmarks.
PAT of INR21 crores, up 11.4% YoY, maintaining a healthy PAT margin of 18.6%.

What to watch

Operating margins moderated QoQ due to higher facility-related expenses, the impact of new labor laws, and appreciation of the rupee.
The food testing business experienced a decline in import and export related sample receipts, primarily due to ongoing global challenges.

Read the full call →

What Vimta Labs does

Vimta Labs is a contract research and testing organisation (CRTO), founded in 1984, that runs accredited laboratories for pharmaceutical, biopharma, agrochemical, food, electronics and environmental clients. It earns fee-for-service revenue across four business lines: drug discovery and development services (pharma analytical, clinical research, preclinical/toxicology studies), food and agri testing, electricals and electronics testing and certification, and environment testing and consultancy. Its labs hold approvals from Indian and global regulators (USFDA, WHO, EMA, MHRA, FSSAI, BIS, OECD-GLP, NABCB among others), letting it serve both domestic manufacturers and overseas pharma/food clients out of its Hyderabad-headquartered network.

Segments

Drug discovery and development services
Food & Agri Testing
Electricals & Electronics Testing & Certification
Environment Testing & Consultancy

Multi-disciplinary workforce: 1,384 employees, 71.11% scientists
Labs and offices across India: 10
Lab infrastructure: 600,000+ sq. ft. of ultra-modern lab space
Experience in the CRTO industry: 41+ years (established 1984)
Regulatory audits cleared: ~100 successful regulatory audits
Market position: #1 in India in Pharma Analytical Testing and in Food Testing; among top 5 in India in Preclinical Research and in Environment Testing; a leading electronics & electricals testing lab in South India

Founded 1984Headquarters Hyderabad, IndiaEmployees 1,384 (FY26 (year ended March 2) Company website

Guidance record · Q1 FY27

what the last two calls moved 12 tracked 2 delivered 3 missed 7 open

Biologics Commercialization delivered said Q1 FY26 Promised: Commercialization of biologics services projected for Q1 FY27 Q1 FY27: Successfully secured the first order for Biologics services and operationalized the facility in Q1 FY27, meeting the projected timeline. Management confirmed: 'The commercialization has begun already in Q1. The client is onboarded in Q1.'
FY26 Annual Revenue missed said Q2 FY26 Promised: Achieve an INR 500 crores (5,000M) annual revenue run rate for FY26 Q1 FY27: This promise for FY26 was concluded as 'missed' in the previous quarter and was not mentioned.
Facility Capacity on track said Q1 FY26 Promised: New facility space will be sufficient for the next 5 years of growth Q1 FY27: Management confirmed the existing infrastructure is sufficient for the next 4-5 years of growth, reiterating the long-term capacity plan.

All 12 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 11.2%, net profit up 10.5% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	85	90	94	98	102 +20%	99 +10%	109 +16%	109 +11%
Expenses	55	57	61	64	68	64	70	72
EBITDA	30	33	33	34	34 +13%	34 +3%	39 +18%	37 +9%
Margin	35%	37%	35%	35%	34%	35%	36%	34%
Other income	-1	5	2	2	3	0	3	4
Interest	0	1	0	0	0	0	0	0
Depreciation	8	10	9	10	10	11	13	13
Profit before tax	20	28	25	25	26 +30%	23 −18%	29 +16%	28 +12%
Tax rate	24%	23%	27%	25%	24%	25%	27%	26%
Net profit	15	22	18	19	20 +33%	18 −18%	21 +17%	21 +11%
EPS	3.44	4.84	4.12	4.24	4.47	3.94	4.73	4.71

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −21.0% 1Y

1Y: ₹796.5 on 10 Sept 2025 → ₹629.6. High ₹825.05 (19 Sept 2025), low ₹380.7 (30 Mar 2026).

How the price took the results

close before → close after

Q1 FY27: −5.2%; 20 Jul
Q4 FY26: +3.2%; 6 May
Q3 FY26: −10.3%; 28 Jan
Q2 FY26: −5.9%; 3 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 9.0% a year over 3 years, FY23 to FY26. Operating margin widened to 34.6%.

Year ending	FY23	FY24	FY25	FY26
Revenue	₹315 Cr	₹292 Cr	₹344 Cr	₹408 Cr
Operating profit	₹94 Cr	₹90 Cr	₹122 Cr	₹141 Cr
Operating margin	29.8%	30.8%	35.5%	34.6%
Interest	₹3 Cr	₹3 Cr	₹1 Cr	₹0 Cr
Depreciation	₹31 Cr	₹33 Cr	₹35 Cr	₹44 Cr
Net profit	₹47 Cr	₹39 Cr	₹67 Cr	₹78 Cr
Net margin	14.9%	13.4%	19.5%	19.1%
Cash from operations	₹87 Cr	₹61 Cr	₹94 Cr	₹147 Cr
Free cash flow	₹37 Cr	₹-14 Cr	₹17 Cr	₹47 Cr
ROCE	24.0%	20.0%	25.0%	25.0%

How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year ending	FY21	FY22	FY23	FY24	FY25	FY26
Equity capital	₹4 Cr	₹4 Cr	₹4 Cr	₹4 Cr	₹9 Cr	₹9 Cr
Reserves	₹190 Cr	₹229 Cr	₹276 Cr	₹338 Cr	₹407 Cr	₹448 Cr
Borrowings	₹30 Cr	₹19 Cr	₹15 Cr	₹12 Cr	₹7 Cr	₹3 Cr
Other liabilities	₹49 Cr	₹54 Cr	₹65 Cr	₹86 Cr	₹95 Cr	₹102 Cr
Total liabilities	₹273 Cr	₹306 Cr	₹360 Cr	₹440 Cr	₹518 Cr	₹562 Cr
Fixed assets	₹128 Cr	₹162 Cr	₹168 Cr	₹183 Cr	₹240 Cr	₹305 Cr
Capital work in progress	₹17 Cr	₹0 Cr	₹12 Cr	₹75 Cr	₹55 Cr	₹18 Cr
Investments	₹6 Cr	₹6 Cr	₹6 Cr	₹0 Cr	₹0 Cr	₹2 Cr
Other assets	₹122 Cr	₹138 Cr	₹174 Cr	₹183 Cr	₹224 Cr	₹237 Cr
Total assets	₹273 Cr	₹306 Cr	₹360 Cr	₹440 Cr	₹518 Cr	₹562 Cr

How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

What the price assumes

Expensive

To justify its price of ₹630, this stock must grow earnings at 25% every year for 7 years. Our analysis caps realistic growth at ~18%. At that growth it is worth ₹438 — downside of 30%.

Growth the price implies: 24.7% a year; for 7 years, fading to 4%
It has actually compounded at: 18.4% a year; net profit, FY23–FY26 · EPS 17.6%
The gap: 0.1 pp; -30% downside if it only repeats history

Price today ₹629.6 Value at the reference growth ₹438.1

Change the assumptions yourself →

All earnings calls (5)

Read the Q1 FY27 call →

Learn to analyse Vimta Labs

Guides on how to read this kind of business and the numbers that matter.